Residual nasal polyp tissue following dupilumab therapy is associated with periostin-associated fibrosis.

Isao Suzaki Yuki Maruyama Sawa Kamimura Kojiro HiranoSatoshi NunomuraKenji IzuharaHitome Kobayashi

Published in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2023)

Dupilumab improves sinonasal symptoms and reduces the nasal polyp score in refractory ECRS. Periostin-associated tissue fibrosis may be involved in the differential effect of dupilumab on nasal polyp reduction.

Keyphrases

atopic dermatitis
chronic rhinosinusitis
physical activity
depressive symptoms
bone marrow